Synethetic DNA producer Twist Bioscience has raised $27m to close its latest round, which includes Kangmei Group, at $60m, taking its total funding to $191m.

The healthy behaviour management platform's latest round was led by Cigna and included Humana, Sanofi, GE, Kaiser Permanente and Providence Health & Services.

Novartis and Alphabet subsidiary Verily were among the limited partners for a the late-stage fund, which will complement the GSK and Johnson & Johnson-backed fund Medicxi closed in 2016.

The telemedicine services provider, which is backed by Cambia Health Solutions, Catholic Health Initiatives and McKesson Ventures, raised the cash from unnamed backers.

IP Group has supported a first funding round for Carma Therapeutics, a University of Pennsylvania spinout that is working on cellular immunotherapies.

The UT Horizon Fund has participated in a $14.3m series B round for Lung Therapeutics.

Serenta, which develops vaccines targeting chronic infections, has obtained a licence for a vaccine against bacteria that have proven resistant to antibiotics.

PharmaCell, a spinout of Brightlands Maastricht Health Campus, has been acquired by Lonza.